ACE2 and COVID-19: The finding that the majority of the SARS‐CoV‐2–neutralizing activity of the polyclonal antibody response in COVID‐19–convalescent patients can be attributed to IgG antibodies directed against conformational but not against sequential RBD epitopes is important because so far only 3 mutations (E484K, N501Y, and K417N) have been observed in the RBD of currently reported SARS‐CoV‐2 variants (https://spikemutants.exscalate4cov.eu/) of which only one (ie, E484K) appears on the RBD surface (Figure S7) but does not seem to be involved in the ACE2 interaction.